Meeting NewsVideo

VIDEO: Neurotech advances cell therapies for macular telangiectasia, glaucoma

NEWPORT BEACH, Calif. — At OCTANe’s Ophthalmology Technology Summit, Richard Small, CPA, CEO of Neurotech Pharmaceuticals, discusses the company’s pipeline, including encapsulated cell therapy, or ECT, for macular telangiectasia.

NEWPORT BEACH, Calif. — At OCTANe’s Ophthalmology Technology Summit, Richard Small, CPA, CEO of Neurotech Pharmaceuticals, discusses the company’s pipeline, including encapsulated cell therapy, or ECT, for macular telangiectasia.

    See more from OCTANe Ophthalmology Technology Summit